Skip to search formSkip to main contentSkip to account menu

PI3K Delta/Gamma Inhibitor RP6530

Known as: RP 6530, RP-6530, RP6530 
An orally active, highly selective, small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
SAFETY AND CLINICAL ACTIVITY OF RP6530, A DUAL PI3Kδ/γ INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES: FINAL ANALYSIS OF A PHASE 1 MULTI‐CENTER STUDY
patients were analyzed by flow cytometry and modeled against CAR T cell levels. In vivo CAR T‐cell levels were measured by qPCR… 
2017
2017
DUAL PI3K δ/γ INHIBITOR RP6530 IN PATIENTS WITH RELAPSED/REFRACTORY T‐CELL LYMPHOMA: DOSE ESCALATION FINDINGS.
tolerated dose (MTD) of len with standard dose CHOEP. Methods: Eligible patients had newly diagnosed PTCL, ANC ≥1000 cells/mm… 
2016
2016
A Dose Escalation Study of RP6530, a Novel Dual PI3K δ/γ Inhibitor, in Patients with Relapsed/Refractory T-Cell Lymphoma
Introduction: The δ isoform of PI3K is highly expressed in cells of hematopoietic origin. The γ isoform is associated with T… 
2016
2016
Clinical Activity and Safety of RP6530, a Dual PI3Kδ/γ Inhibitor, in Patients with Advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multicenter Study
Introduction: RP6530 is a novel, next generation, highly specific dual PI3K δ/γ inhibitor with nano-molar inhibitory potency… 
2016
2016
Abstract 3331: RP6530, a dual PI3K δ/γ inhibitor attenuates cancer stem cell proliferation in serous adenocarcinoma of ovary
The overall survival of patients with advanced serous adenocarcinoma of the ovary (EOC) has not significantly improved for the… 
2015
2015
A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies
Introduction: Phosphoinositide-3-kinases (PI3Ks) are pivotal in cell proliferation and survival, cell differentiation… 
2015
2015
Abstract A24: The dual PI3K δ/γ inhibitor, RP6530, in combination with ibrutinib or fludarabine, synergistically enhances cytotoxicity in primary CLL cells in vitro.
Background: The PI3K pathway is a central pro-survival mechanism in chronic lymphocytic leukemia (CLL). While the delta isoform… 
2015
2015
Abstract 2420: The dual PI3K δ/γ inhibitor RP6530 in combination with Brentuximab Vedotin (SGN-35) synergistically induces cell death via inhibition of tubulin polymerization in Hodgkin lymphoma cell…
2014
2014
Addition of RP6530, a Dual PI3Kδ/γ Inhibitor, Overcomes Ibrutinib Resistance in DLBCL Cells in Vitro
Background: Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive, rapidly growing type of lymphoma that comprises of 30-40% of… 
2013
2013
Dual PI3Kδ/γ Inhibition By RP6530 Induces Apoptosis and Cytotoxicity In B-Lymphoma Cells
Introduction Activation of the PI3K pathway triggers multiple events including cell growth, cell cycle entry, cell survival and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)